QIBA PET Tau Biomarker Committee (BC)
Friday, December 8, 2023, at 9 am CT
Call Summary
Notes derived in part from Ms. Matthews' slides

In attendance

Tammie Benzinger, MD, PhD (co-chair)
Dawn Matthews, MS, MBA (co-chair)
Tobey James Betthauser, PhD, MS
Charlie Chen, PhD
Rachid Fahmi, MSc, PhD

Norman Foster, MD
Lauren Koenig, PhD
Antoine Leuzy, PhD
Richard Margolin, MD

Nancy Obuchowski, PhD
John Seibyl, MD
Jean-Luc Vanderheyden, PhD
Dean F. Wong MD, PhD

RSNA Staff

Julie Lisiecki

Progress since November meeting
- Dr. Vanderheyden has prepared outreach wording for when the Profile is ready to be sent out for public comment
- Additional Profile input has been received and consolidated into the draft Profile (posted to Dropbox)
- Dropbox folder contents to be moved to a new Box and invitations to BC members will be sent soon
- Dr. Leuzy has not received a response yet from the *Alzheimer's and Dementia* journal regarding possible publication
    - Dr. Benzinger to follow up with a contact of hers at the journal before other options are considered

Profile Updates
- It was agreed that the group of tracers will not be pooled for the wCV measurements and will be measured in a tracer-specific manner; stating the range would be acceptable
- An Overview Table of Factors will be added for better Profile navigation, as the Profile is 100+ pages
- Test-retest literature may need to be reviewed for age ranges
- A future developments section was proposed
- The BC is still planning to release the Profile for public comment in December pending BC and CC voting processes if successfully completed before December 22nd

Ongoing action items
- Targeted SME lists to be developed for public comment to include pharma contacts and SNMMI
- Dr. Betthauser to inquire about the 2022 Human Amyloid Imaging (HAI) attendee list, as well as a specialized Neuro-imaging committee contact list from the Alzheimer's Association for public comment SMEs

Next Steps
- Final group editing
- Complete use cases
- Circulate for public comment
- Verify technical conformance (clinical feasibility, Stage 3) in parallel
- Profiles can be submitted for QUIC endorsement after December following the process posted on the QIBA Wiki

Proposed Timeline
- Public comment timelines – minimum of 30 days is planned
- December – BC/CC voting to release (if successfully completed before December 22nd) and then send out Profile for public comment
- January – address feedback received

Updated Schedule (12.08.2023):

	August	September	October	November	December	January
Planning						
Decide on plan forward (Profile by year end)	✅					
Sign up for Profile ingredients		✅				
Claim Development						
Literature review	✅					
Initial wCV calculations based upon literature	✅					
Decision regarding pooling vs. separate wCV per tracer	✅					
Additional data (internal ADNI analysis, other)		✅				
Consensus wCVs						
Bias analysis for cross sectional claim(s)		not done				
Translate to Cases		first pass	refine			
Profile Drafting: Other sections (amyloid adaptation/tailoring)						
Internal review		✅				
Public Comment and Incorporate Feedback				30 days	30 days	
Technical Confirmation (assuming same as amyloid)						
Final Profile Posting						
Manuscript Development						
Literature Review as context for claims						
Profile description						
Group Review and Submit						

References

QIBA PET Amyloid Profile	QIBA FDG-PET/CT Profile
QIBA SPECT Ioflupane Profile, v2 (example of cross-sectional claim)	
QIBA US SWS Profile (example of cross-sectional claim)	
QIBA LinkedIn page	QIBA Twitter page
QIBA Videos	
Consensus (Stage 2): Comment Resolution Spreadsheet	
Clinically Feasible (Stage 3): Feedback Resolution Spreadsheet	
http://tinyurl.com/QIBA-Public-Comment-Form	